MK-5618
Total Payments
$2.1M
Transactions
245
Doctors
2
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $1.2M | 130 | 1 |
| 2019 | $926,436 | 114 | 0 |
| 2018 | $900.00 | 1 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.1M | 243 | 99.6% |
| Consulting Fee | $7,438 | 2 | 0.4% |
Payments by Type
Research
$2.1M
243 transactions
General
$7,438
2 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase Ib Multi-center Clinical Study of Selumetinib MK-5618 in Combination with Pembrolizumab MK-3475 in Participants with Metastatic Solid Tumors | Merck Sharp & Dohme Corporation | $2.0M | 0 |
| A Phase Ib Multi-center Clinical Study of Selumetinib (MK-5618) in Combination with Pembrolizumab (MK-3475) in Participants with Metastatic Solid Tumors | Merck Sharp & Dohme Corporation | $64,985 | 0 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $2.1M
- Total Doctors 2
- Transactions 245
About MK-5618
MK-5618 is a drug associated with $2.1M in payments to 2 healthcare providers, recorded across 245 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2018 to 2020. In 2020, $1.2M was paid across 130 transactions to 1 doctors.
The most common payment nature for MK-5618 is "Unspecified" ($2.1M, 99.6% of total).
MK-5618 is associated with 2 research studies, including "A Phase Ib Multi-center Clinical Study of Selumetinib MK-5618 in Combination with Pembrolizumab MK-3475 in Participants with Metastatic Solid Tumors" ($2.0M).